Results 251 to 260 of about 1,671,061 (305)

Age and CMV are not associated with clinical or immunological response to immune checkpoint blockade

open access: yes
Edwards JM   +7 more
europepmc   +1 more source

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo   +2 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs   +2 more
openaire   +2 more sources

Immune checkpoint inhibitors and vasculitis

Current Opinion in Rheumatology, 2020
Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland   +2 more
openaire   +2 more sources

Immune checkpoint receptors in autoimmunity

Current Opinion in Immunology, 2023
Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT) have distinct and overlapping inhibitory functions that regulate Tcell activation, differentiation, and function.
Kelly P, Burke   +3 more
openaire   +2 more sources

Epigenetics Meets Immune Checkpoints

Seminars in Oncology, 2015
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties.
Covre A.   +5 more
openaire   +3 more sources

Immune Checkpoint Therapies for Melanoma

Hematology/Oncology Clinics of North America, 2021
Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are approved for the treatment of advanced melanoma alone and in combination.
openaire   +2 more sources

Home - About - Disclaimer - Privacy